| Targeted virus . | FIV . | HIV . | HCV . | HPIV3 . | HSV1 . | INFVA . | RSV . | SARS-CoV . |
|---|---|---|---|---|---|---|---|---|
| Positive samples | 101 | 867 | 438 | 87 | 213 | 112 | 119 | 137 |
| Negative samples | 2561 | 1795 | 2224 | 2575 | 2449 | 2550 | 2543 | 2525 |
| Targeted virus . | FIV . | HIV . | HCV . | HPIV3 . | HSV1 . | INFVA . | RSV . | SARS-CoV . |
|---|---|---|---|---|---|---|---|---|
| Positive samples | 101 | 867 | 438 | 87 | 213 | 112 | 119 | 137 |
| Negative samples | 2561 | 1795 | 2224 | 2575 | 2449 | 2550 | 2543 | 2525 |
| Targeted virus . | FIV . | HIV . | HCV . | HPIV3 . | HSV1 . | INFVA . | RSV . | SARS-CoV . |
|---|---|---|---|---|---|---|---|---|
| Positive samples | 101 | 867 | 438 | 87 | 213 | 112 | 119 | 137 |
| Negative samples | 2561 | 1795 | 2224 | 2575 | 2449 | 2550 | 2543 | 2525 |
| Targeted virus . | FIV . | HIV . | HCV . | HPIV3 . | HSV1 . | INFVA . | RSV . | SARS-CoV . |
|---|---|---|---|---|---|---|---|---|
| Positive samples | 101 | 867 | 438 | 87 | 213 | 112 | 119 | 137 |
| Negative samples | 2561 | 1795 | 2224 | 2575 | 2449 | 2550 | 2543 | 2525 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
